ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree

As Amgen strives to become the industry’s top player in cardiometabolic risk reduction by the start of the next decade, the company took to the American Diabetes Association 2026 Scientific Session | As Amgen strives to become the top player in cardiometabolic risk reduction by the start of the next decade, the company took to the American Diabetes Association 2026 Scientific Sessions in New Orleans this past weekend to bolster the case for its cholesterol-lowering blockbuster Repatha in a high-risk patient subgroup.